Financial Statements of

## HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL

And Independent Auditors' Report thereon

Year ended March 31, 2021



KPMG LLP Vaughan Metropolitan Centre 100 New Park Place, Suite 1400 Vaughan ON L4K 0J3 Canada Tel 905-265-5900 Fax 905-265-6390

#### INDEPENDENT AUDITORS' REPORT

To the Members of Holland Bloorview Kids Rehabilitation Hospital

#### **Report on the Financial Statements**

#### Opinion

We have audited the financial statements of Holland Bloorview Kids Rehabilitation Hospital (the Entity), which comprise:

- the statement of financial position as at March 31, 2021
- the statement of revenue and expenses for the year then ended
- the statement of changes in net assets for the year then ended
- the statement of remeasurement gains and losses for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2021, and its results of operations, its changes in net assets, its remeasurement gains and losses, and its cash flows for the year then ended in accordance with Canadian public sector accounting standards.

#### Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditors' Responsibilities for the Audit of the Financial Statements" section of our auditors' report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Page 2

### Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian public sector accounting standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

#### Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

#### We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
  - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.



#### Page 3

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other
  matters, the planned scope and timing of the audit and significant audit findings,
  including any significant deficiencies in internal control that we identify during our
  audit.

#### Report on Other Legal and Regulatory Requirements

As required by the Corporations Act (Ontario), we report that, in our opinion, the accounting policies applied in preparing and presenting financial statements in accordance with Canadian public sector accounting standards have been applied on a basis consistent with that of the preceding year.

Chartered Professional Accountants, Licensed Public Accountants

Vaughan, Canada

KPMG LLP

May 27, 2021

Statement of Financial Position

March 31, 2021, with comparative information for 2020

		2021		2020
Assets				
Current assets:				
Cash	\$	7,344,386	\$	5,860,869
Due from the Ministry of Health (notes 2 and 15)		4,072,818		719,051
Accounts receivable (note 2)		3,307,333		3,748,369
Other assets		180,174		157,201
Due from related parties (note 9)		1,771,531		4,580,621
		16,676,242		15,066,111
Investments (note 3)		49,515,752		36,440,206
Property, plant and equipment (note 4)		75,549,913		76,148,409
	\$	141,741,907	\$	127,654,726
Current liabilities: Accounts payable and accrued liabilities (note 5)	\$	15,617,219	\$	16,404,569
Due to the Ministry of Health	Ψ	1,884,129	Ψ	438,775
Due to the Ministry of Fleditin		17,501,348		16,843,344
Deferred contributions (note 6) Deferred capital grants and donations -		10,265,017		7,619,133
spent and unamortized (notes 7 and 15)		64,554,606		62,923,409
Deferred capital grants and donations - unspent (note 8)		15,437,303		13,222,458
		107,758,274		100,608,344
Net assets:				
Accumulated operating surplus		27,422,921		25,264,300
Accumulated remeasurement gains		6,560,712		1,782,082
		33,983,633		27,046,382
	\$	141,741,907	\$	127,654,726

See accompanying notes to financial statements.

Approved by the Board of Trustees:

Truste Truste

Marg Rappolt

Chair, Board of Trustees

Trustee Trustee

Allyson Whyte Nowak Treasurer, Board of Trustees

Statement of Revenue and Expenses

Year ended March 31, 2021, with comparative information for 2020

		2021		2020
Revenue:				
Province of Ontario (note 15)	\$	73,272,317	\$	66,911,332
One-time working funds funding (note 16)		1,599,500		, , <u> </u>
Client services and other		10,959,438		13,470,060
Foundation grants and donations (note 9)		9,020,889		10,200,009
Other operating grants		6,394,356		7,694,904
Investment income - net		1,971,490		2,268,798
Amortization of deferred capital grants and donations		1,371,680		1,297,834
		104,589,670		101,842,937
Expenses:				
Salaries and benefits (note 10)		81,380,623		79,905,947
Supplies and other (note 11)		17,673,858		19,973,087
Amortization of furniture and equipment		2,734,033		2,513,798
		101,788,514		102,392,832
Excess (deficiency) of revenue over expenses before				(= 1 = = = )
undernoted items		2,801,156		(549,895)
Amortization of deferred capital grants and donations		0.004.000		0.750.070
related to building and building equipment		3,631,838		2,756,672
Amortization of building and building aguinment		(4 204 000)		(2 207 070)
Amortization of building and building equipment		(4,284,988)		(3,387,970)
Excess (deficiency) of revenue over expenses	\$	2,148,006	\$	(1,181,193)
LAGESS (MEIIGIETICY) OF TEVELINE OVER EXPENSES	φ	2,140,000	φ	(1,101,193)

Statement of Changes in Net Assets

Year ended March 31, 2021, with comparative information for 2020

					2021	2020
	Investment in property, plant and	Restricted for	Restricted for property and building			
	equipment	endowments	redevelopment	Unrestricted	Total	Total
	(note 7)		•			
Balance, beginning of year	\$ 13,225,000	\$ 1,746,535	\$ 4,081,708	\$ 6,211,057	\$ 25,264,300	\$ 26,392,444
Excess (deficiency) of revenue over expenses before						
undernoted items Amortization of building and	(1,362,353)	_	_	4,163,509	2,801,156	(549,895)
building equipment	(4,284,988)	_	_	_	(4,284,988)	(3,387,970)
Amortization of deferred capital grants and donations related to	0.004.000				0.004.000	0.750.070
building and building equipment	3,631,838	_			3,631,838	2,756,672
Excess (deficiency) of revenue over expenses for the year	(2,015,503)	-	_	4,163,509	2,148,006	(1,181,193)
Net purchase of property, plant and equipment Amounts funded by deferred capital	6,420,525	_	_	(6,420,525)	_	-
grants and donations	(6,634,715)	_	_	6,634,715	_	_
Net change in investment in property, plant and equipment	(214,190)	_	_	214,190	_	
Contributions - net of expenses	-	10,615	_	-	10,615	53,049
Balance, end of year	\$ 10,995,307	\$ 1,757,150	\$ 4,081,708	\$ 10,588,756	\$ 27,422,921	\$ 25,264,300

Statement of Remeasurement Gains and Losses

Year ended March 31, 2021, with comparative information for 2020

						2021	2020
	Investment in property, plant and equipment (note 7)	estricted for ndowments	a	Restricted for property and building evelopment	Unrestricted	Total	Total
	(note 1)						
Accumulated remeasurement gains, beginning of year	\$ _	\$ 189,802	\$	509,536	\$ 1,082,744	\$ 1,782,082	\$ 6,562,260
Unrealized gains (losses)	_	309,518		1,296,980	3,172,132	4,778,630	(3,993,242)
Amounts reclassed to the statement of revenue and expenses	_	_		_	_	_	(786,936)
Accumulated remeasurement gains, end of year	\$ _	\$ 499,320	\$	1,806,516	\$ 4,254,876	\$ 6,560,712	\$ 1,782,082
Summary by fund: Accumulated operating surplus Accumulated remeasurement	\$ 10,995,307	\$ 1,757,150	\$	4,081,708	\$ 10,588,756	\$ 27,422,921	\$ 25,264,300
gains	_	499,320		1,806,516	4,254,876	6,560,712	1,782,082
	\$ 10,995,307	\$ 2,256,470	\$	5,888,224	\$ 14,843,632	\$ 33,983,633	\$ 27,046,382

Statement of Cash Flows

Year ended March 31, 2021, with comparative information for 2020

	2021	2020
Cash provided by (used in):		
Operating activities:		
Excess (deficiency) of revenue over expenses Items not affecting cash:	\$ 2,148,006	\$ (1,181,193)
Amortization of property, plant and equipment	7,019,021	5,901,768
Amortization of deferred capital grants and donations	(5,003,518)	(4,054,506)
Change in non-cash operating working capital (note 14)	531,390	583,502
	4,694,899	1,249,571
Investing activities:		
Redemption (purchase) of investments - net	(6,082,071)	3,713,183
Purchase of property, plant and equipment	(6,420,525)	(8,913,042)
	(12,502,596)	(5,199,859)
Financing activities:		
Capital grants and donations received	6,634,715	6,725,185
Deferred contributions	2,645,884	(573,314)
Endowment contributions received, net of expenses	10,615	53,049
	9,291,214	6,204,920
Increase in cash	1,483,517	2,254,632
Cash, beginning of year	5,860,869	3,606,237
Cash, end of year	\$ 7,344,386	\$ 5,860,869

Notes to Financial Statements

Year ended March 31, 2021

Holland Bloorview Kids Rehabilitation Hospital ("Holland Bloorview") is Canada's largest children's rehabilitation teaching hospital, fully affiliated with the University of Toronto.

Holland Bloorview was incorporated without share capital under the laws of Ontario and is registered as a charitable organization under the Income Tax Act (Canada) and, accordingly, is exempt from income taxes provided certain requirements of the Income Tax Act (Canada) are met.

Under the Health Insurance Act (Ontario) and the Local Health System Integration Act 2006, Holland Bloorview is funded primarily by the Province of Ontario through the Ministry of Health (the "MOH") and in accordance with budget arrangements established by Toronto Central Local Health Integration Network ("TC LHIN"). These financial statements reflect agreed funding arrangements approved by the TC LHIN with respect to the year ended March 31, 2021. Subsequent to Holland Bloorview's signing of the agreements with the TC LHIN, the province's LHINs have amalgamated and are now part of Ontario Health.

#### 1. Significant accounting policies:

#### (a) Basis of accounting and presentation:

The financial statements have been prepared by management in accordance with Canadian public sector accounting standards ("PSAS"), including standards that apply to government not-for-profit organizations. The financial statements reflect the total services of Holland Bloorview, which include clinical, educational and research activities for children and youth with disabilities. The financial statements do not include the assets, liabilities, operations and cash flows of Holland Bloorview Kids Rehabilitation Hospital Foundation (the "Foundation"), which is a separate entity.

#### (b) Revenue recognition:

Holland Bloorview follows the deferral method of accounting for contributions.

Operating grants are recorded as revenue in the year to which they relate. Grants approved but not received at the end of an accounting year are accrued to offset incurred expenses.

Unrestricted contributions are recognized as revenue when they are received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Externally restricted contributions other than endowment contributions are deferred and recognized as revenue in the year in which the related expenses are incurred.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 1. Significant accounting policies (continued):

Endowment contributions are recognized as direct increases in endowment net assets when received.

Revenue from all other sources is recognized when the services are provided.

Investments comprise funds invested in externally managed balanced pooled funds. Income distributions from these pooled funds and realized gains and losses, net of fees are recognized in investment income in the statement of revenue and expenses.

Investment income, both realized and unrealized, is attributed to unspent deferred capital grants where there is either an implicit or explicit restriction on income.

#### (c) Property, plant and equipment:

Purchased property, plant and equipment are recorded at cost. Contributed property, plant and equipment are recorded at fair value at the date of contribution. Costs incurred that substantially increase the useful lives of existing property, plant and equipment are capitalized. Costs to maintain normal operating efficiency are expensed as incurred.

Property, plant and equipment are amortized on a straight-line basis over their useful lives as follows:

Building equipment5 - 40 yearsBuilding40 yearsFurniture and equipment5 - 20 yearsSoftware5 years

In accordance with PSAS, Holland Bloorview reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable and exceeds its fair value. The impairment loss is measured as the extent to which the carrying amount exceeds the fair value.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 1. Significant accounting policies (continued):

#### (d) Deferred capital grants and donations:

Capital grants and donations received as funding for property, plant and equipment additions are initially deferred and realized in revenue on the same basis as the amortization of the cost of the related property, plant and equipment.

#### (e) Restricted net assets for endowment:

All of the net assets restricted for endowment purposes are subject to externally imposed restrictions, stipulating that the principal be maintained intact. Investment income earned on resources restricted for endowments is reported in the restricted for endowments fund or the unrestricted fund, depending on the nature of any restrictions imposed by contributors of funds for endowment.

#### (f) Contributed services and materials:

A substantial number of volunteers contribute a significant amount of their time each year. Because of the difficulty in determining the fair value, contributed services are not recognized in the financial statements.

#### (g) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Financial instruments, such as cash and investments are reported at fair value. All other financial instruments, including accounts receivable, due from the MOH, due from related parties, accounts payable and accrued liabilities and due to the MOH, are recorded at amortized cost.

Unrealized changes in fair value are recognized in the statement of remeasurement gains and losses until they are realized, when they are transferred to the statement of revenue and expenses.

All financial assets are assessed for impairment on an annual basis. When a decline in value is determined to be other than temporary, the amount of loss is reported in the statement of revenue and expenses.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 1. Significant accounting policies (continued):

The standards require Holland Bloorview to classify fair value measurements using a fair value hierarchy, which includes three levels of information that may be used to measure fair value:

- Level 1 unadjusted quoted market prices in active markets for identical assets or liabilities;
- Level 2 observable or corroborated inputs, other than Level 1, such as quoted prices
  for similar assets or liabilities in inactive markets or market data for substantially the full
  term of the assets or liabilities; and
- Level 3 unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

#### (h) Use of estimates:

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting year.

Significant items subject to such estimates and assumptions include the carrying amounts of accounts receivable and property, plant and equipment. Actual results could differ from those estimates.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 2. Accounts receivable:

	2021	2020
Accounts receivable Less allowance for doubtful accounts	\$ 3,431,480 124,147	\$ 4,117,665 369,296
	\$ 3,307,333	\$ 3,748,369
	0004	2000

	2021	2020
Due from Ministry of Health ("MOH") Less allowance for doubtful accounts	\$ 5,883,807 1,810,989	\$ 797,983 78,932
-	\$ 4,072,818	\$ 719,051

#### 3. Investments:

Investments are carried at fair value and consist of the following:

2021	Level 1	Level 2	2 Level 3	Total
Balanced Pooled Funds	\$ 49,350,752	\$ -	- \$ 165,000	\$ 49,515,752

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 4. Property, plant and equipment:

			2021	2020
		Accumulated	Net book	Net book
	Cost	amortization	value	value
Land Building equipment Building Furniture and equipment Software	\$ 138,478 26,374,794 91,036,424 30,424,967 11,632,311	\$ - 17,323,692 32,646,054 25,126,392 8,960,923	\$ 138,478 9,051,102 58,390,370 5,298,575 2,671,388	\$ 138,478 11,376,513 55,930,515 5,472,978 3,229,925
	\$ 159,606,974	\$ 84,057,061	\$ 75,549,913	\$ 76,148,409

During the year, Holland Bloorview wrote off no amount (2020 - \$192,000) of fully amortized assets.

#### Building redevelopment:

Holland Bloorview completed construction of a new facility at a final cost of \$107 million in 2007. In connection with this redevelopment project, there was \$713,376 (2020 - \$713,376) in outstanding letters of credit as at March 31, 2021.

#### 5. Accounts payable and accrued liabilities:

Included in accounts payable and accrued liabilities are government remittances payable of \$411,470 (2020 - \$1,520,609), which includes amounts payable for harmonized sales tax and payroll-related taxes.

#### 6. Deferred contributions:

Deferred contributions represent unspent externally restricted grants and donations for research and other purposes.

	2021	2020
Balance, beginning of year Amounts received or receivable Amounts recognized as revenue	\$ 7,619,133 28,840,152 (26,194,268)	\$ 8,192,447 26,210,595 (26,783,909)
Balance, end of year	\$ 10,265,017	\$ 7,619,133

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 7. Deferred capital grants and donations - spent and unamortized:

Deferred capital grants and donations represent the spent and unamortized amount for the purchase of property, plant and equipment. The amortization of capital grants and donations is recorded as revenue in the statement of revenue and expenses.

	2021	2020
Balance, beginning of year Capital grants and donations received Amortization of deferred capital grants and donations	\$ 62,923,409 6,634,715 (5,003,518)	\$ 61,387,489 5,590,426 (4,054,506)
Balance, end of year	\$ 64,554,606	\$ 62,923,409

#### 8. Deferred capital grants and donations - unspent:

	2021	2020
Balance, beginning of year Capital gains reinvested Unrealized remeasurement gain (loss)	\$ 13,222,458 - 2,214,845	\$ 13,723,690 1,134,759 (1,635,991
Balance, end of year	\$ 15,437,303	\$ 13,222,458

Cumulative remeasurement gains as at March 31, 2021 totalled \$3,601,171 (2020 - \$1,386,323).

#### 9. Related party transactions:

The Foundation is an independent corporation without share capital which has its own board of directors. The Foundation was established to raise funds to support Holland Bloorview and its programs and capital needs. The Foundation is responsible for fundraising activities carried out on behalf of Holland Bloorview and donations or bequests made to Holland Bloorview are recorded as revenue by the Foundation.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 9. Related party transactions (continued):

During the year, the Foundation granted \$13,809,442 (2020 - \$15,100,031) to Holland Bloorview to fund programs and capital expenditures. The balance due from the Foundation of \$1,771,531 (2020 - \$4,580,621) comprises grants payable from the Foundation and operating expenses paid by Holland Bloorview on behalf of the Foundation. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by both parties.

#### 10. Pension plan:

Substantially all of the employees at Holland Bloorview are members of the Healthcare of Ontario Pension Plan, which is a defined benefit multi-employer contributory pension plan. The plan is accounted for as a defined contribution plan. Employer contributions made to the plan during the year by Holland Bloorview amounted to \$5,205,536 (2020 - \$5,118,465). These amounts are included in salaries and benefits expenses in the statement of revenue and expenses. The most recent actuarial valuation of the plan as at December 31, 2018 indicated the plan was fully funded on a going concern basis.

#### 11. Centralized equipment pool:

Holland Bloorview is responsible for administering the provincial program that provides equipment on loan or lease as communication aids for people with disabilities. This equipment is accounted for in a manner similar to the treatment of prescription drugs and is expensed when prescribed. The amount charged to supplies and other expenses in the statement of revenue and expenses for the purchase of equipment for lease is \$2,791,453 (2020 - \$2,785,100). These costs are funded by the MOH.

#### 12. Contingent liability:

Holland Bloorview is a member of the Healthcare Insurance Reciprocal of Canada ("HIROC") and, therefore, has an economic interest in HIROC. HIROC is a pooling of the public liability insurance risks of its hospital members. All members of the HIROC pool pay annual premiums, which are actuarially determined, and are subject to assessment for losses in excess of such premiums, if any, experienced by the pool for the years in which they were a member. No such assessments have been made for the year ended March 31, 2021.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 13. Financial risks and concentration of risk:

#### (a) Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations, resulting in a financial loss. Holland Bloorview is exposed to credit risk in the event of non-payment by patients for non-insured services and services provided to non-resident patients. The risk is common to hospitals as they are required to provide care for patients regardless of their ability to pay for services provided.

Holland Bloorview assesses, on a continuous basis, accounts receivable and provides for any amounts that are not collectible in the allowance for doubtful accounts. The maximum exposure of credit risk to Holland Bloorview at March 31, 2021 is the carrying value of these assets.

#### (b) Market risk:

Market risk is the risk that the fair value of financial instruments or future cash flows associated with financial instruments fluctuate because of changes in market prices other than those arising from interest rate risk. Holland Bloorview is exposed to market risk through its investments.

As at March 31, 2021, Holland Bloorview's total exposure to other market risk is \$49,515,752. Holland Bloorview's estimate of the effect on net assets as at March 31, 2021 due to a 5% increase or decrease in the fair value of investments, with all other variables held constant, would approximately amount to an increase or decrease of \$2,475,788. In practice, the actual trading results may differ from this sensitivity analysis and the difference could be material.

#### (c) Interest rate risk:

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Holland Bloorview is exposed to interest rate risk as a result of cash balances. As at March 31, 2021, Holland Bloorview's estimate of the exposure to interest rate risk and the effect on net assets is not material.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 14. Statement of cash flows:

Change in non-cash operating working capital related to operations is as follows:

	2021	2020
Due from the MOH	\$ (3,353,767)	\$ (51,883)
Accounts receivable	441,036	282,862
Other assets	(22,973)	(20,795)
Due from related parties	2,809,090	(3,857,431)
Accounts payable and accrued liabilities	(787,350)	4,513,224
Due to the MOH	1,445,354	(282,475)
	\$ 531,390	\$ 583,502

#### 15. Ministry of Health pandemic funding:

In connection with the ongoing coronavirus pandemic ("COVID-19"), the Ministry of Health ("MOH") has announced a number of funding programs intended to assist hospitals with incremental operating and capital costs and revenue decreases resulting from COVID-19. In addition to these funding programs, the MOH is also permitting hospitals to redirect unused funding from certain programs towards COVID-19 costs, revenue losses and other budgetary pressures through a broad-based funding reconciliation.

While the MOH has provided guidance with respect to the maximum amount of funding potentially available to Holland Bloorview, as well as criteria for eligibility and revenue recognition, this guidance continues to evolve and is subject to revision and clarification subsequent to the time of approval of these financial statements. The MOH has also indicated that all funding related to COVID-19 is subject to review and reconciliation, with the potential for adjustments during the subsequent fiscal year.

Management's estimate of MOH revenue for COVID-19 is based on the most recent guidance provided by MOH and the impacts of COVID-19 on the Hospital's operations, revenue and expenses. As a result of management's estimation process, the Hospital has determined a range of reasonably possible amounts that are considered by management to be realistic, supportable and consistent with the guidance provided by the MOH. However, given the potential for future changes to funding programs that could be announced by the MOH, the Hospital has recognized revenue related to COVID-19 based on the lower end of the range. Any adjustments to management's estimate of MOH revenue will be reflected in the Hospital's financial statements in the year of settlement.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 15. Ministry of Health pandemic funding (continued):

Details of the MOH funding for COVID-19 recognized as revenue in the current year are summarized below:

Funding for incremental COVID-19 operating expenses Funding for temporary pandemic pay Funding for COVID-19 assessment center Funding for revenue losses resulting from COVID-19	\$	4,346,168 724,252 126,160 2,711,800
Turiding for revenue recession recurring from CCV12 To		7,908,380
		1,000,000
Less provision for future changes to funding programs		1,787,898
	\$	6.120.482
	Ψ	0,120,402

In addition to the above, the Hospital has also recognized \$97,900 in MOH funding for COVID-19 related capital expenditures, which has been recorded as an addition to deferred capital contributions during the year.

#### 16. Ministry of Health working capital funding:

In March 2021, the Hospital was advised that it was eligible for one-time funding to address its working capital deficit. The Hospital is eligible to receive this funding based on defined eligibility criteria with the stipulation that the funding will only be used to reduce the Hospital's working capital deficit and is not to be used for operating purposes.

As at the date of approval of these financial statements, the MOH has provided a preliminary estimate of working capital funding and has indicated that the final amount of funding is subject to further analysis and validation by the MOH. Any future adjustments to working capital funding will be reflected in the Hospital's financial statements in the year of settlement.

Notes to Financial Statements (continued)

Year ended March 31, 2021

#### 17. COVID-19 impacts:

In response to COVID-19 and consistent with guidance provided by the MOH and other government agencies, the Hospital has implemented a number of measures to protect patients and staff from COVID-19. In addition, the Hospital has actively contributed towards the care of COVID-19 patients and the delivery of programs that protect public health.

The Hospital continues to respond to the pandemic and plans for continued operational and financial impacts during the 2022 fiscal year and beyond. Management has assessed the impact of COVID-19 and believes there are no significant financial issues that compromise its ongoing operations. The outcome and timeframe to a recovery from the current pandemic is highly unpredictable, thus it is not practicable to estimate and disclose its effect on future operations at this time.